BRCA2 and prostate cancer: Indeed, in the context of the IMPACT study, BRCA2 P/LPV carriers (n = 902) had a higher incidence of prostate cancer, younger age of diagnosis, and clinically significant tumors compared with non-carriers (n = 497) [115].